Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to $21.2 million.

  • Vanda Pharmaceuticals' Prepaid Assets rose 7995.58% to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.2 million, marking a year-over-year increase of 7995.58%. This contributed to the annual value of $15.4 million for FY2024, which is 6815.7% up from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Prepaid Assets stood at $21.2 million for Q3 2025, which was up 7995.58% from $22.2 million recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Prepaid Assets ranged from a high of $25.7 million in Q2 2022 and a low of $6.6 million during Q1 2023
  • Its 5-year average for Prepaid Assets is $15.0 million, with a median of $13.4 million in 2021.
  • Its Prepaid Assets has fluctuated over the past 5 years, first plummeted by 7394.59% in 2023, then soared by 18982.31% in 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Prepaid Assets (Quarter) stood at $12.0 million in 2021, then surged by 47.77% to $17.7 million in 2022, then plummeted by 48.27% to $9.2 million in 2023, then soared by 68.16% to $15.4 million in 2024, then skyrocketed by 37.23% to $21.2 million in 2025.
  • Its last three reported values are $21.2 million in Q3 2025, $22.2 million for Q2 2025, and $20.5 million during Q1 2025.